Please login to the form below

Not currently logged in
Email:
Password:

cardiovascular diseases

This page shows the latest cardiovascular diseases news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca forms $2bn gene silencing pact with Silence Tx

AstraZeneca forms $2bn gene silencing pact with Silence Tx

Collaboration focuses on cardiovascular, renal, metabolic and respiratory disease. UK biotech Silence Therapeutics has added to its growing stable of pharma partnerships with a wide-ranging collaboration with AstraZeneca in cardiovascular,

Latest news

More from news
Approximately 5 fully matching, plus 97 partially matching documents found.

Latest Intelligence

  • Can protein degraders unlock ‘undruggable’ drug targets? Can protein degraders unlock ‘undruggable’ drug targets?

    Drug discovery is almost entirely focused on controlling protein activity to treat or cure diseases, using small-molecule or biologics to inhibit or in some cases boost the activity of a ... Big pharma and new start-ups. Arvinas recently attracted a $750m

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    He says the company is “very confident” of sustaining growth in China, and says its broad portfolio of medicines across oncology, respiratory and cardiovascular, metabolic and renal will help it achieve ... diseases, cardiovascular diseases,

  • Finding the patient voice Finding the patient voice

    rheumatoid arthritis, oncology, psychiatry, cardiovascular diseases, rare diseases etc.

  • Deal Watch December 2016 Deal Watch December 2016

    1, 850. Bicycle (UK). AstraZeneca (UK). Licence collaboration. Bicycle platform: small molecules with antibody specificity for targets in respiratory, cardiovascular and metabolic diseases. ... 320. Evotec (Germany). Celgene (US). Discovery collaboration.

  • A healthy challenge A healthy challenge

    Vytenis told PME he is “very concerned” about the rising burden of chronic non-communicable diseases, such as cardiovascular diseases, cancer and type 2 diabetes. ... The risk of developing these diseases is very much increased due to some of our

More from intelligence
Approximately 0 fully matching, plus 17 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Switzerland
Switzerland: a life sciences hub
Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
Responding to dynamic shifts in value communications
OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
Doing what we can and having fun doing it: our fundraising month
Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...

Infographics